Quest Diagnostics (NYSE:DGX – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current ratings for Quest Diagnostics and Mangoceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quest Diagnostics | 0 | 6 | 5 | 1 | 2.58 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Quest Diagnostics currently has a consensus target price of $237.85, suggesting a potential upside of 2.69%. Given Quest Diagnostics’ stronger consensus rating and higher probable upside, research analysts clearly believe Quest Diagnostics is more favorable than Mangoceuticals.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quest Diagnostics | $11.04 billion | 2.32 | $992.00 million | $9.42 | 24.59 |
| Mangoceuticals | $315,227.00 | 26.48 | -$20.64 million | ($1.01) | -0.38 |
Quest Diagnostics has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Quest Diagnostics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
Profitability
This table compares Quest Diagnostics and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quest Diagnostics | 9.18% | 16.01% | 7.27% |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
Summary
Quest Diagnostics beats Mangoceuticals on 12 of the 15 factors compared between the two stocks.
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
